Skip to main content
. Author manuscript; available in PMC: 2014 Apr 14.
Published in final edited form as: JAMA. 2011 Jun 8;305(22):2327–2334. doi: 10.1001/jama.2011.746

Figure 3. Overall Survival and Time to Progression of All 25 Patients and Those With Recurrent or Sporadic Mutations.

Figure 3

Kaplan-Meier curves for overall survival (15 deaths) and time to progression (22 progression events) of the 25 evaluable patients are shown. The median overall survival was 10.7 months (95% confidence interval [CI], 6.5 months-not achieved) and the median time to progression was 2.8 months (95% CI, 2.5–4.0 months). Mutations repeatedly identified in melanoma or gastrointestinal stromal tumors and those associated with a mutated to wild-type allele ratio of more than 1 are those most likely to be pathogenetically relevant. The subset of patients with tumors harboring such alterations achieved an overall survival and time to progression greater than that achieved in cases without such characteristics.